Targeted Genomic Analysis of Human Cancers
The purpose of this study is to identify potentially "actionable" genomic alterations in cancers using next-generation sequencing technology, with a focus on rare cancers and cancers for which there is limited standard therapy. The overall hypothesis of this protocol is that actionable mutations are present in a significant subset of patients with cancers for which there is no effective curative therapy. To test this hypothesis, the aims of this study are as follows:
1.1. To obtain blood and tumor tissue for next-generation sequencing and determine the frequency of finding genomic alterations for which there are clinically available (commercially or research based) targeted therapies. Treating clinicians will be provided with relevant validated mutation data for treatment or referral of the patient to pertinent studies.
1.2. To collect clinical outcomes of patients for which sequencing has been performed.
1.3. To obtain whole tumor genome data for data storage and future computational analysis and correlation with clinical data.
1.4. To obtain tumor tissue for development of future in vitro and in vivo cancer models.
- Rutgers Cancer Institute of New Jersey
- RWJBarnabas Health
- Jersey City Medical Center, Jersey City
- Karnofsky/Lansky performance score >= 30
- A signed written informed consent
- Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of
biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with
standard therapy; priority will be given to rare cancers with poor prognosis and lack
of effective standard therapy; study principal investigator (PI) or designee will
review and approve each case before enrollment
- Paraffin blocks of the patient's tumor tissue are available and accessible for
- Karnofsky/Lansky performance score < 30
- Life expectancy < 3 months
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.